Atlas Trials

Indivior Inc.

51 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Indivior Inc.

RecordFirmDate
INDV-6001 Multiple-Dose Pharmacokinetic Study (NCT06576843)Indivior Inc.2024-09-17
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder (NCT06384157)Indivior Inc.2024-06-10
Evaluating the SUBLOCADE Treatment Exit Strategy (NCT05878210)Indivior Inc.2023-11-24
SUBLOCADE Long-term Outcomes (NCT05860959)Indivior Inc.2023-08-31
Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants (NCT05974046)Indivior Inc.2023-07-10
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations (NCT05704543)Indivior Inc.2023-03-01
Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder (NCT04976855)Indivior Inc.2022-08-17
Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users (NCT04995029)Indivior Inc.2021-10-26
An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term (NCT04577144)Indivior Inc.2020-09-20
INDV-2000 First in Human (NCT04413552)Indivior Inc.2020-07-06
SUBLOCADE Rapid Initiation Extension Study (NCT04060654)Indivior Inc.2019-10-21
SUBLOCADE Rapid Initiation Study (NCT03993392)Indivior Inc.2019-08-29
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone (NCT03978832)Indivior Inc.2019-06-28
Evaluation of Long-term Buprenorphine Plasma Exposure (NCT03752528)Indivior Inc.2019-02-19
Buprenorphine-Fentanyl Interaction Study (NCT03747341)Indivior Inc.2018-03-22
Study of a Novel Subcutaneous Depot Formulation of Buprenorphine (NCT03715634)Indivior Inc.2017-09-20

Track Indivior Inc. automatically

Every clearance here is in the API, with alerts when new ones post.